Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

Back to Search
Print
Bookmark Trial

NCT01206361

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav

- Greater than 18 years old

- Diagnosed with glaucoma or ocular hypertension

- Registered at the primary care practice for > 12 months

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- None

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Glaucoma, Ocular HypertensionStudy to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
NCT00402493
  1. Willingboro, New Jersey
  2. Philadelphia, Pennsylvania
  3. Philadelphia, Pennsylvania
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionNon-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
NCT01012245
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionA Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742
  1. Artesia, California
  2. Atlanta, Georgia
  3. Atlanta, Georgia
  4. North Dartmouth, Massachusetts
  5. Minneapolis, Minnesota
  6. Durham, North Carolina
  7. Koebenhavn OE,
  8. Catania,
  9. Coimbra,
  10. Lisboa,
  11. Mayfair West,
  12. Madrid,
  13. Madrid,
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionComparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US
NCT00847483
  1. Belleflower, California
  2. Inglewood, California
  3. San Diego, California
  4. San Diego, California
  5. San Francisco, California
  6. Gainesville, Florida
  7. Lakeland, Florida
  8. Ormond Beach, Florida
  9. Atlanta, Georgia
  10. Bloomingdale, Illinois
  11. Evansville, Indiana
  12. Louisville, Kentucky
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bangor, Maine
  16. Kansas City, Missouri
  17. Kansas City, Missouri
  18. Omaha, Nebraska
  19. Las Vegas, Nevada
  20. Bloomfield, New Jersey
  21. Willingboro, New Jersey
  22. Charlotte, North Carolina
  23. Winston-Salem, North Carolina
  24. Streetsboro, Ohio
  25. Oklahoma City, Oklahoma
  26. Tulsa, Oklahoma
  27. Pittsburgh, Pennsylvania
  28. Charleston, South Carolina
  29. Charleston, South Carolina
  30. Charleston, South Carolina
  31. Maryville, Tennessee
  32. Memphis, Tennessee
  33. Dallas, Texas
  34. El Paso, Texas
  35. Houston, Texas
  36. Layton, Utah
  37. Norfolk, Virginia
  38. Norfolk, Virginia
  39. Virginia Beach, Virginia
  40. Wenatchee, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
Official Title Persistence Of Use Of Topical Prostaglandin Fixed Dose Combination In The United Kingdom Primary Care: An Observational Study In Thin
Brief Summary The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population patients who had received a prescription for either Xalacom, Ganfort and DuoTrav, > 18 years old, diagnosed with glaucoma or ocular hypertension, registered at the primary care practice for > 12 months
Condition
  • Glaucoma
  • Ocular Hypertension
Intervention
  • Drug: XALACOM
    Xalacom eye drops
  • Drug: Duotrav
    Duotrav eye drops
  • Drug: Ganfort
    Ganfort eye drops
Study Groups/Cohorts fixed dose prostaglandin combination
Interventions:
  • Drug: XALACOM
  • Drug: Duotrav
  • Drug: Ganfort
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 20, 2010)		2015
Original Estimated Enrollment Same as current
Actual Study Completion Date August 2010
Actual Primary Completion Date August 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav
  • Greater than 18 years old
  • Diagnosed with glaucoma or ocular hypertension
  • Registered at the primary care practice for > 12 months

Exclusion Criteria:

  • None
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01206361
Other Study ID Numbers A6111145
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2011